Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A peripherally-acting μ-opioid
antagonist that acts to reverse some of theside effects ofopioid drugs such asconstipation without affectinganalgesia or precipitatingwithdrawals .
Etymologies
from Wiktionary, Creative Commons Attribution/Share-Alike License
Support
Help support Wordnik (and make this page ad-free) by adopting the word methylnaltrexone.
Examples
-
The late pharmacologist Leon Goldberg of the University of Chicago developed a solution drug called methylnaltrexone (MNTX) in the 1980s that blocks the negative side effects of morphine while preserving its pain relieving capabilities.
Signs of the Times 2010
-
RELISTOR (methylnaltrexone bromide or "methylnaltrexone"), administered via subcutaneous injection, is a peripherally acting mu-opioid receptor antagonist that decreases the constipating effects of opioid pain medications in the gastrointestinal tract without affecting their ability to relieve pain.
-
News of the setback hammered stock of Progenics, which considers the intravenous drug, methylnaltrexone, its lead product.
Wyeth-Progenics Drug 2008
-
Roche Holding of Switzerland hopes to introduce Actemra for rheumatoid arthritis, and Progenics Pharmaceuticals and its partner Wyeth are awaiting approval of methylnaltrexone, aimed at preventing digestive problems caused by painkillers.
-
But with the help of Progenics' partner, Wyeth, Farmer said methylnaltrexone should get to market around the same time as alvimopan.
-
"We believe the Street should be newly attracted to the potential of Progenics' methylnaltrexone in the greater than $1 billion OBD indication," said Farmer, giving Progenics shares an "outperform" rating.
-
Wachovia Securities analyst George Farmer, in a note to investors Tuesday, said the disappointing alvimopan results represent "a major setback" and will delay the companies' new drug application filing by at least one year, opening the door for methylnaltrexone.
-
Progenics' management has indicated it plans to file a new drug application for methylnaltrexone in early 2007.
-
Adolor and partner GlaxoSmithKline announced its alvimopan treatment, which is competitive to Progenics' methylnaltrexone, only met its endpoint in one phase III trial but not in the other.
-
RELISTOR methylnaltrexone bromide is a peripherally acting mu-opioid receptor antagonist that decreases the constipating effects of opioid pain medications without affecting their ability to relieve pain.
unknown title 2011
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.